Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with stage IV squamous cell carcinoma of the oesophagus (a specific type of advanced oesophageal cancer), confirmed by a tissue or cell sample, and who are planned to receive a combination of a PD-1 immunotherapy drug and a TP chemotherapy regimen.
• People whose general physical functioning falls within a certain range on a standard medical scale (rated 0–2 on the ECOG scale, meaning able to carry out at least some daily activities — confirm with trial site).
• People who have at least one tumour that can be measured on scans.
• People whose life expectancy is expected to be more than 3 months.
• People who have had previous cancer treatment where any side effects from that treatment have returned to their normal baseline levels, or are at a mild level (grade 1 or below), before joining the trial (except for ongoing hair loss from prior treatment).
• People of reproductive age who agree to use effective contraception from the time of signing the consent form until 6 months after the last dose of the study drug — this applies to both male and female participants and their partners.
• People whose blood test results meet specific health thresholds, including healthy enough levels of white blood cells, platelets, haemoglobin, liver function markers, and kidney function (confirm specific values with trial site).

Who may not be able to join:

• People who currently have, or have a history of, an autoimmune disease that is likely to come back (such as lupus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, or psoriasis), or people who are considered at risk of immune-related complications (for example, organ transplant recipients who require immune-suppressing medication).
• People who have needed to take steroid medications (such as prednisone above a certain dose) or other immune-suppressing drugs within the 14 days before starting the study treatment.
• People who have had major surgery, high-dose radiation therapy, or palliative radiation therapy within the 14 days before starting study treatment, or certain radioactive treatments within the 56 days before starting.
• People who have received any systemic cancer treatment — including immunotherapy or certain biological therapies — within the 14 days before starting study treatment.
• People who have had certain lung conditions, such as interstitial lung disease, inflammation of the lungs, pulmonary fibrosis, or acute lung disease (with some exceptions — confirm with trial site), or who have uncontrolled diabetes or uncontrolled high blood pressure.
• People living with HIV.
• People who currently have active tuberculosis.
• People who have had an active infection requiring intravenous (IV) antibiotic or antiviral treatment within the 2 weeks before the first dose.
• People who have previously received a solid organ transplant.
• People who have previously received any immunotherapy drug that targets immune checkpoint proteins, such as anti-PD-1 or anti-PD-L1 treatments.

Important: Always verify eligibility with the trial site directly before applying.